AI brief of an SEC Form 8-K · Amn Healthcare Services (AMN)

AMN Healthcare Q3 revenue falls 19% to $687.5 million; GAAP EPS $0.18

Negative Impact 4 of 5 earnings Written later

AMN Healthcare reported third quarter 2024 revenue of $687.5 million, down 19% from a year earlier, with GAAP diluted EPS of $0.18 versus $1.39 and adjusted diluted EPS of $0.61 versus $1.97. The company guided fourth quarter revenue to $685 million to $705 million, 14% to 16% below the prior year, and separately amended its credit agreement to allow a higher maximum net leverage ratio through December 31, 2025.

Key points

  • Q3 2024 revenue was $687.5 million, down 19% from $853.5 million in Q3 2023; net income was $7.0 million versus $53.2 million
  • Fourth quarter 2024 guidance: revenue of $685 million to $705 million and operating margin of 1.8% to 2.5%
  • Fourth Amendment dated November 5, 2024 raises the maximum Consolidated Net Leverage Ratio to 4.50 to 1.00 for December 31, 2024 through December 31, 2025, reverting to 4.00 to 1.00 afterward
  • Net leverage ratio was 2.8 to 1.0 at September 30, 2024, and the company reduced debt by $60 million in the quarter

The filing

CompanyAmn Healthcare Services (AMN)
Form8-K, current report
Filed with the SECNov 7, 2024, 4:16 PM ET
Accession number0000950142-24-002692

Items reported: 1.01 Material Definitive Agreement2.02 Results of Operations2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 07, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.